FILING ANALYSIS · FRIDAY, NOVEMBER 13
Annovis Bio, Inc. ANVS — 8-K: Results of Operations and Financial Condition
negative
Annovis Bio raised $21 million in gross proceeds through an underwritten public offering, which will be used to fund operations, but this capital raise represents dilution for existing shareholders. The company also provided updates on its clinical trials, including the DUET-AD study, which is expected to have a data readout in March 2027.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →